You should simply download 143-085 study guide questions and answers

killexams.com helps a large number of applicants pass the exams and get their Certifications. We have a large number of successful audits. Our 143-085 braindumps are dependable, latest, updated, and of the really best quality to beat the challenges of any IT certifications. Killexams 143-085 Practice Test are collected from real 143-085 exams, thats why no doubt in passing the 143-085 exam with hight marks.

Exam Code: 143-085 Practice exam 2022 by Killexams.com team
Brocade Certified Fabric Professional Gen 5
Brocade Professional test
Killexams : Brocade Professional test - BingNews https://killexams.com/pass4sure/exam-detail/143-085 Search results Killexams : Brocade Professional test - BingNews https://killexams.com/pass4sure/exam-detail/143-085 https://killexams.com/exam_list/Brocade Killexams : Here's the Secret to Passing Military Fitness Tests

We all have heard not to "train for the test" when it comes to tactical fitness, and this statement is true. However, the results of a test will determine whether you get into the military as a recruit, stay in the military or advance to more selective training (special ops, Officer Candidate School (OCS), ROTC, service academy).

These tests matter significantly to your future. While it is true that training for the fitness test that includes push-ups, sit-ups, and a 1.5-mile run is only preparing you for the test and perhaps not the actual demands of a military job, there is a time when training specifically for the test is necessary.

The acronym used to describe an ideal fitness program is FITT, which stands for frequency, intensity, time and type. The secret to passing any fitness test is found in this acronym.

Frequency

You must practice consistently to see results. This schedule can be every other day on a regular basis for several weeks, months or daily, depending on your preference and abilities. If you're looking to pass a fitness test, this would mean to do your testing events every other day if upper-body calisthenics and running are on the test.

If you needed to limit your overall volume of running, you could do your calisthenics, followed by a run of test length on Monday, Wednesday and Friday. On the days in between, you could mix in some non-impact cardio and leg calisthenics (squat, lunges) to aid in preparing the legs and lungs for the running event, minus the impact.

Intensity

When you practice running and calisthenics for a fitness test, intensity also matters. Get used to running and doing higher-repetition calisthenics at a goal pace well above the minimum standards. Time spent doing longer, slower distances may not be the best option if you need to run a short and fast pace in order to pass a PT test.

For both the calisthenics and the cardio events of a PT test, moving with a purposeful pace is the key to your success. If you need to do 80 sit-ups in two minutes, you need to work on a pace of 20 sit-ups in 30 seconds and build up to two minutes.

The same goes for the run pace. If you need to run a seven-minute mile, you need to practice the pace of 1:45 for 400 yards and 3:30 for 800 yards to eventually do a seven-minute mile pace for the distance of your PT Test.

Time

The amount of time each day you devote to the test is also important, but it does not have to be hours. In fact, you can block out 15 minutes of calisthenics workouts in the morning and 15 minutes of running in the afternoon if time is tight for you on any given day.

The time you spend each day (or every other day) on fitness can be molded to fit into your schedule. After all, most fitness tests in the military take from less than 15 minutes to 30 minutes of actual exertion time as they advance.

The most important factor of time is consistency and frequency of your training. You will typically need a four- to eight-week phase of training before your test for best results.

Type (Specifics)

This is the key. No matter what you are testing, your workouts must be specific to the exercises being tested if you want to Strengthen those test scores. If it is the events of the Army Combat Fitness Test (ACFT), then get in the weight room and mix lifting (deadlift) with calisthenics, shuttle runs with weight and two-mile run workouts.

If it is simply calisthenics (push-ups, pull-ups, sit-ups or plank, and run), then you can do more with less equipment as you specifically train for the test.

Your success with this type of training also depends on your technique and how you efficiently perform the exercises. Practice is needed, but perfect practice is preferred.

You do not want to spend your entire year training specifically for a test, though the newer tactical fitness tests like the ACFT represent better models of training that force practicing strength, power, speed and agility, as well as the standard muscle stamina and cardio endurance (basic calisthenics and cardio PT tests).

Depending on your job and your future goals, your ability to get good at all the tactical elements of fitness may be required. Do not neglect training specifically for objective graded events as well as the more all-encompassing physical challenges of the day-to-day activities in the profession.

Stew Smith is a former Navy SEAL and fitness author certified as a Strength and Conditioning Specialist (CSCS) with the National Strength and Conditioning Association. Visit his Fitness eBook store if you're looking to start a workout program to create a healthy lifestyle. Send your fitness questions to stew@stewsmith.com.

Want to Learn More About Military Life?

Whether you're thinking of joining the military, looking for fitness and basic training tips, or keeping up with military life and benefits, Military.com has you covered. Subscribe to Military.com to have military news, updates and resources delivered directly to your inbox.

Show Full Article

© Copyright 2022 Military.com. All rights reserved. This material may not be published, broadcast, rewritten or redistributed.

Fri, 16 Sep 2022 07:55:00 -0500 en text/html https://www.military.com/military-fitness/heres-secret-passing-military-fitness-tests
Killexams : Premium Quality Nepali Silk Brocade

Vous n'avez pas encore de compte

Je m'abonne pour lire tous les magazines en ligne et accéder à plus de 4 000 tutoriels.

Je créé un compte pour recevoir mes newsletters et gérer mes données personnelles.

Wed, 21 Sep 2022 12:31:00 -0500 fr text/html https://www.marieclaire.fr/idees/recettes-creatives,2615464.asp1
Killexams : An immortal spectacle
Photo: www.chinadaily.com.cn

Photo: www.chinadaily.com.cn

BEIJING, 10 October (BelTA - China Daily). - At the Niya ruins site in the Xinjiang Uygur autonomous region, an antique brocade armband, with embroidered characters roughly translating to "five stars rise in the east and benefit China", left many with room for imagination.

For the crew of dance drama Eastern Immortal Prophecy, the artifact from the Han Dynasty (206 BC-AD 220) contains an epic about the empire, a northern nomadic tribe and the kingdom of Jingjue, which is what Niya used to be. The story tells of a border-defending commander who captures a tribal chief's son, yet the two get lost in the desert and end up in Jingjue, where the pair, and the princess of the kingdom, develop a friendship.

At the recent 13th China Art Festival, the dance drama was given the Wenhua Grand Prize, a top accolade for the performing arts in the country.

Director Wang Ge says this is the most difficult production he has worked on, because the subject matter required imagination, and the historical background meant their creation would need to be attested by records.

"The Niya ruins site has such a long history, and we could only find limited historical material for reference, but a dance drama needs a lot of supporting details," Wang says.

The creation of the dance drama started in February 2020. By June that year, the crew went on trips to Xinjiang's Urumqi and Hotan cities to gather inspiration from the ancient site and about the artifacts.

A wooden slip found at the site reads, "Feng greets Chunjun by presenting this jade ornament. Let's not forget about each other." From the artifact, scriptwriter of the production Xu Rui came up with the characters for Feng and Chunjun, respectively the commander and princess, and hence weaved this story about unity among ethnic groups.

The crew revised 12 drafts before deciding on a final script that adopts a humorous and lighthearted storyline to portray the seemingly irreconcilable differences of the protagonists.

"This grand narrative seemed heavy to present, so we decided to use a comedic way in the plot, so as to make the production more acceptable for the general audience, and bridge the gap between history and today," Wang says.

Gulmira Mamat, an associate professor at Minzu University of China, plays the role of Chunjun. Although she is an experienced dancer, she specializes in solo dance, and this is the first dance drama she has participated in.

"Performing in a dance drama is a test of a dancer's comprehensive abilities. In addition to professional dancing skills, we need to be able to portray a character, express the emotions and tell a story," she says.

Although she is different from the story's teenage girl Chunjun, Gulmira Mamat says she has enjoyed playing the character, whose zesty and whimsical nature made the performing experience liberating.

"We are telling a story that is based in my hometown, but more than 2,000 years ago. I feel that I've traveled in time to a fairy-tale world, and taken the other two protagonists on a trip around beautiful Xinjiang," she says.

"By performing in the dance, I have once again gotten to know the charms of Xinjiang's culture. I'm very honored to work with an excellent team, and grateful for my hometown, nourishing me with its songs, dances and diverse culture, and allowing me to have my own unique performing style."

The dance drama premiered in Beijing in June 2021, and toured China, delivering more than 30 performances in just over a year. Apart from the national tour, several seminars centered on the production were hosted, where experts gave their opinions and suggestions, based on which the team continued to modify the production.

Wang Yichuan, vice-chairman of China Literature and Art Critics Association, said at a seminar that the dance drama is marked by its integration of performing arts and archaeology, using dance to envision the stories behind cultural relics.

"This production can provide valuable inspiration for artistic creation. China has many historical artifacts, just like this brocade piece, waiting to exercise the imagination of artists of different genres, and to inject life into these treasures in a contemporary context," Wang Yichuan says.

Sun, 09 Oct 2022 18:37:00 -0500 en-EN text/html https://eng.belta.by/partner_news/view/an-immortal-spectacle-153694-2022/
Killexams : These tests tell you which foods to avoid. Do they work?

OHIO — Food is one of life’s pleasures, but it can also be a source of pain — especially if you’re among the tens of millions of Americans who regularly experience digestive issues such as heartburn, abdominal pain, bloating or diarrhoea. When those symptoms strike, you may wonder: Are certain foods to blame?

Food-sensitivity tests promise to supply answers. For decades, these tests were offered mainly in providers’ offices in alternative-medicine settings. Now, they are increasingly available as at-home tests you can purchase online or on drugstore shelves. Manufacturers claim that with several drops of blood or a few plucked hairs, they can identify the foods that are causing your discomfort. Once eliminated from your diet, you’ll be on the road to relief.

That a simple test could guide dietary changes and Strengthen common, disruptive symptoms is certainly appealing. But do these tests work? We asked some experts and looked into the research to find out.

What is a food sensitivity, anyway?

According to Dr David Stukus, director of the Food Allergy Treatment Center at Nationwide Children’s Hospital in Columbus, Ohio, the term food sensitivity is used more in marketing than in medicine. “There really is no consensus definition of what a food sensitivity is,” he said.

The companies selling these tests typically describe it as what happens when a specific food triggers digestive issues or gut inflammation, causing symptoms such as abdominal pain, bloating or headaches. Symptoms may appear hours or even days after eating, and often resolve when the offending food is avoided.

When physicians or dietitians refer to such issues, they’re more likely to use the term food intolerance, Dr Stukus said (although some may use food sensitivity, too), such as with lactose intolerance, which can cause constipation, diarrhoea and bloating as a result of difficulty digesting the sugar found in milk.

Similarly, people with irritable bowel syndrome, or IBS, may be sensitive to certain kinds of carbohydrates called FODMAPs, and altering their diet may relieve their symptoms.

A food intolerance or sensitivity is different from a food allergy, Dr Stukus said, which is an immune reaction to certain foods that can cause more severe symptoms such as vomiting, hives, shortness of breath or even life-threatening anaphylaxis, usually within minutes of eating even a small amount. There are also more chronic immune reactions to foods, such as those from celiac disease, a serious autoimmune condition triggered by gluten.

How do food-sensitivity tests work?

At-home food-sensitivity test kits can be ordered online or purchased over-the-counter at drugstores. Depending on the test type, you’ll pluck several hairs or prick your finger to drop blood onto a paper card, and then mail in your sample. Within days or weeks, you’ll receive digital results, including a list of foods that may be causing problems.

Some tests claim to determine your sensitivity to hundreds of foods and ingredients by measuring the “bioresonance” of your hair, an unproven technique used in holistic or complementary medicine that involves measuring the energy wavelengths coming from your body. Others measure the levels of certain antibodies, called IgG antibodies, in your blood.

Still other tests, called Alcat and MRT tests, require a blood draw from a lab and measure how the size of your blood cells change after exposure to food extracts in a test tube, said Dr John Kelso, an allergist at Scripps Clinic Carmel Valley in San Diego.

Are food-sensitivity tests accurate?

Aside from the breath tests that gastroenterologists sometimes use to diagnose certain intolerances, such as those to lactose or fructose, there aren’t validated tests for food intolerances or sensitivities, said Dr Tamara Duker Freuman, a registered dietitian at New York Gastroenterology Associates in New York City.

The only way to figure out if you are sensitive to certain foods or ingredients is to see how your symptoms change after eliminating them from your diet, ideally with the help of a registered dietitian or physician, she said.

This can be a slow process involving trial and error, and the companies selling food-sensitivity tests market them as a shortcut. But medical organisations, including those in the United States, Europe and Canada, have recommended against using food sensitivity or intolerance tests because there is no good evidence that they work.

“There isn’t anything in your hair that would tell you anything about your sensitivity to food,” Dr Kelso said. And the antibodies measured in the IgG tests are produced as part of the immune system’s normal response to foods; they haven’t been shown to correlate with symptoms or intolerances, Dr Stukus said.

“It’s really just a reflection of what you’ve eaten.”

Ms Christina Song, a spokesperson for Everlywell, a company that sells at-home IgG food-sensitivity tests, pointed to several studies — mostly in people with IBS and some funded by the companies that sell the tests. In them, researchers found that eliminating high IgG foods reduced symptoms such as abdominal pain and bloating.

But, in general, many of the studies that have reported positive results for food-sensitivity tests have been small and often lacked proper control groups, said Dr Lin Chang, a gastroenterologist and professor of medicine at the David Geffen School of Medicine at UCLA.

In a small trial of 58 IBS patients, published in 2017 and funded by Cell Science Systems, a company that sells the Alcat food sensitivity test, researchers found that those who avoided foods flagged as intolerant by the test for four weeks reported greater improvement in their symptoms than control participants.

Are there any downsides to trying these tests?

There can be. Food sensitivity testing can cause people to unnecessarily avoid a long list of foods, missing out on those they enjoy and potentially becoming susceptible to nutrient deficiencies, said Dr Frances Onyimba, a gastroenterologist and assistant professor of medicine at the University of Maryland School of Medicine.

The cost of food sensitivity testing is generally not covered by insurance and can range from less than US$100 (S$140) for hair-based tests to US$600 or more for tests on blood-cell size. The Everlywell Food Sensitivity Comprehensive Test retails online for US$299.

The tests can also leave people anxious about eating, which can sometimes develop into eating disorders, Dr Stukus said.

This article originally appeared in The New York Times.

Sat, 01 Oct 2022 03:34:00 -0500 en text/html https://www.todayonline.com/world/these-tests-tell-you-which-foods-avoid-do-they-work-1996926
Killexams : The touching story behind Princess Mary's iconic pink brocade Carla Zampatti gown

By Matilda Rudd For Daily Mail Australia 00:14 06 Oct 2022, updated 00:14 06 Oct 2022

  • A new exhibition in Sydney set to open in November will honour Carla Zampatti
  • Princess Mary once asked to keep a pink brocade dress made by the designer
  • She wore it to a number of special occasions, including for royal photographs
  • There will be 100 designs on display at the Powerhouse Museum next month 

An upcoming exhibition featuring the late fashion designer Carla Zampatti's greatest works has drawn particular focus to a gown Princess Mary wore a number of times, including for official royal photographs.

The Australian-born Danish royal originally wore the pink brocade dress in 2013 for The Australian Women's Weekly's 80th anniversary cover shoot, before asking Zampatti herself whether she could take it home.

It appeared two years later on the Princess as she posed alongside her husband Prince Frederik in their private residence, Frederik VIII's Palace, inside the Amalienborg complex, in Copenhagen in 2015.

The Australian-born Danish royal originally wore the pink brocade dress in 2013 for The Australian Women's Weekly's 80th anniversary cover shoot, before asking Zampatti herself whether she could take it home
It appeared two years later on the Princess as she posed alongside her husband Prince Frederik in their private residence, Frederik VIII's Palace, inside the Amalienborg complex, in Copenhagen in 2015

'At the end of the shoot she asked if she could keep the dress [and] I was delighted,' Zampatti later told Fairfax Media.

'She looks so beautifully regal in their 2015 official portraits. I am so proud.'

Shot by photographer Franne Voigt Mary accessorised the dress with the Queen Ingrid Ruby parure, which have become her most frequently worn tiara, necklace and bracelet set.

The iconic pink dress also made an appearance behind closed doors in March 2014 when Mary wore it to a dinner inside Amalienborg Palace held in honour of Turkish President Abdullah Gul and his wife Hayrunnisa Gul. 

'At the end of the shoot she asked if she could keep the dress [and] I was delighted,' Zampatti (pictured) later told Fairfax Media
The royal is known for championing Australian designers - including Scanlan and Theodore - on the world stage

The royal is known for championing Australian designers - including Scanlan and Theodore - on the world stage.

'When I was asked to design a gown for Princess Mary, I was thrilled. She is such a beautiful representation for this country,' Zampatti added.

The fashion designer died in April 2021 after an accidental fall at the Opera House in Sydney saw her fail to recover. She was 78. 

The new exhibition, which will honour Zampatti's 50-year career and include the pink dress, will be held at Sydney's Powerhouse Museum from November.

There will be 100 other designs on display, including ex Prime Minister Julia Gillard's jacket worn when she addressed US Congress in 2011 and the white jacket worn by Christine Holgate when speaking at the Australia Post Inquiry in April 2021.

Wed, 05 Oct 2022 12:14:00 -0500 en text/html https://www.dailymail.co.uk/femail/real-life/article-11285005/amp/The-touching-story-Princess-Marys-iconic-pink-brocade-Carla-Zampatti-gown.html
Killexams : Experts share the 5 best pregnancy tests of 2022 and where to buy them

Let’s face it. You either landed on this page because you’re crossing your fingers for a little bundle of joy, or you’re praying for anything but that. Nonetheless, you’re here, and we want to say it’ll all be okay.

But who better to talk about all things pregnancy than a doctor? Enter Dr. Kenosha Gleaton, board certified doctor in gynecology and obstetrics and medical director of Natalist — a women’s health startup that provides products and resources for fertility and pregnancy.

We spoke with Dr. Kenosha about the best pregnancy tests out there, when to take a test, how soon you can take one and more.

While we gathered expert insight, we still recommend reaching out to your doctor for full assurance.

FAQs with Dr. Kenosha

How do pregnancy tests work?

“Pregnancy tests detect a hormone called human Chorionic Gonadotropin (hCG), which can be detected in urine or blood after an embryo implants itself into your uterine wall,” Dr. Kenosha told The New York Post. “hCG is the first detectable sign of pregnancy, and home tests (like the Natalist Pregnancy Test and Natalist Early Pregnancy Test Strips) are an easy and reliable way to determine if you’re pregnant.”

When should you take a pregnancy test?

Dr. Kenosha explained that testing first thing in the morning before your expected period is usually your best bet, as your urine “has a higher concentration of hCG” at that time Though, you can test at any time of the day.

Dr. Kenosha also notes that “drinking lots of liquids in the few hours before testing can dilute your urine and cause a false negative result.” This meaning you could be pregnant, but the test will show you’re not.

Furthermore, “14% to 25% of women have irregular menstrual cycles, which can make it harder to predict when to test,” said Dr. Kenosha. “If this is you, try counting at least 14 days from when you had sex. If your test says you’re not pregnant and you think you might be, test again the next day or in a few days.”

All of this to say, it can be tricky to know exactly when to test, but there are a few methods that can help out.

How soon can you take a pregnancy test?

Taking a pregnancy test too soon is a thing, though, “it varies based on a test’s sensitivity rate so be sure to read the directions thoroughly,” explained Dr. Kenosha.

“You can use most pregnancy tests starting five days before you expect your period to start,” she continued. “If you get a negative result and are testing more than three days before your expected period, you could still be pregnant and should take another test in a few days.”

The reason for this is that you could be early in your pregnancy, meaning “you may not have enough hCG for the test to detect yet,” Dr. Kenosha told The Post. Though, in just two days, your hCG levels will usually double, meaning the more likely it is to get a positive result.

How accurate are pregnancy tests?

“Pregnancy tests are more than 99% accurate in clinical studies when used on the day of your expected period,” shared Dr. Kenosha. Still, false negatives are a thing. This means hCG was not detected in your urine, though you actually are pregnant.

Dr. Kenosha says false negatives happen for two reasons. First, “your urine was too diluted” or “it’s too early to detect a pregnancy.”

Truth be told, false positives are a thing too, though they’re more unlikely.

To avoid false test results, Dr. Kenosha recommends seeing your doctor to confirm your outcome.

Best pregnancy tests

1. Best pregnancy test strips: Natalist Early Pregnancy Test Strips, $16

Best pregnancy tests
Natalist

Both reliable and affordable, these early pregnancy test strips deliver you peace of mind ASAP. Proven to be over 99% accurate and ringing in as low as 85 cents per test, these Natalist test strips are a fan favorite. Not to mention, Natalist doesn’t produce electronic waste from batteries or other components found in many digital pregnancy tests.


2. Best early response pregnancy test: First Response Early Result Pregnancy Test, 3 Count, $13, original price: $20

Best pregnancy tests
Amazon

In just three minutes, you will have an answer as to whether you are pregnant or not — even if it’s six days sooner than your missed period. Pair these tests with the EasyRead App which is over 99% accurate for full assurance.


3. Best digital pregnancy test: Clearblue Pregnancy Test Combo Pack, $10

Best pregnancy tests
Target

Say goodbye to confusing lines and markings with this digital pregnancy test. It will clearly display your results by either practicing “Pregnant” or “Not Pregnant.” In the pack is also a Clearblue Rapid Detection Pregnancy Test that will offer you positive (+) or negative (-) results.


4. Best pregnancy test subscription: Stix Pregnancy Tests, $12 every four weeks

Best pregnancy tests
Stix

Always have a test on hand with this Stix pregnancy test subscription service. You will be able to know whether you’re pregnant up to three days before your missed period.


5. Best First Response Triple Check Pregnancy Test Kit, $15

Best pregnancy tests
Target

Tripple-check your results with this pack of three First Response tests. This pack provides you with three different ways to test.


Check out New York Post Shopping for more content.

Thu, 22 Sep 2022 03:56:00 -0500 en-US text/html https://nypost.com/article/best-pregnancy-tests-per-experts/
Killexams : Roche to introduce its next-generation portfolio of SARS-CoV-2 rapid antigen tests (“2.0”) under CE Mark for self-test and professional use

F. Hoffmann-La Roche Ltd

  • Broad and trusted portfolio of COVID-19 rapid tests feature innovative updates and enhanced performance, building on insights gained throughout the pandemic

  • All tests now work seamlessly with navify® Pass, Roche’s digital solution that allows individuals and healthcare professionals to immediately store, display, and share COVID-19 vaccination status and test results through a unique data matrix

  • Roche maintains the capacity to provide tens of millions tests each month to meet sustained high worldwide demand from individuals and healthcare professionals

Basel, 12 October 2022- Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced the launch of its next-generation portfolio SARS-CoV-2 rapid antigen tests (“2.0”) for self-testing and professional use in countries accepting the CE Mark. Distribution of the new rapid test portfolio is projected to begin in the coming weeks.

In doing so, Roche builds upon one of the broadest portfolios of COVID-19 rapid testing solutions with three new test configurations that feature enhanced performance through the use of an improved capture antibody and the addition of new digital data sharing capabilities to all tests. Using nasopharyngeal and nasal swab samples, respectively, the tests deliver reliable results in as few as 15 minutes, aiding in the diagnosis of SARS-CoV-2 infection in individuals with or without symptoms consistent with COVID-19.

“The continued evolution of the SARS-CoV-2 virus and COVID-19 pandemic reinforce the need for individuals and healthcare systems to have access to the most reliable rapid testing solutions possible,” said Thomas Schinecker, CEO, Roche Diagnostics. “As a leader in diagnostic innovation, we are proud to be one of the first among our industry to apply insights gained from the past two years toward a next-generation rapid test portfolio. These tests are ready to support global society as we navigate this next phase of the pandemic.”

The three tests set to launch are the following:

Professional use:

Self-Test:

Roche maintains the capacity to provide several tens of millions of each of the tests per month, with the option to quickly build up additional capacity if needed, to address sustained high worldwide demand for rapid testing from governments, healthcare systems and individuals. The next-generation test portfolio will be introduced in partnership with SD Biosensor Inc., with whom Roche has a global distribution agreement and previously launched a range of rapid antigen and antibody tests in more than 50 countries worldwide.

The tests join Roche Diagnostics’s broader COVID-19 portfolio, which includes a wide range of molecular, serological and digital solutions that help diagnose and manage COVID-19 during the initial stages of infection, during the recovery phase, and following the resolution of infection.

About the next-generation portfolio of SARS-CoV-2 rapid antigen tests (“2.0”)
Lab testing showed that all three tests can qualitatively detect major variants of concern including Delta and Omicron variants. Emerging variants are continuously monitored.

SARS-CoV-2 Rapid Antigen Test 2.01 (nasopharyngeal sampling)
The SARS-CoV-2 Rapid Antigen Test 2.0 is a rapid chromatographic immunoassay for the qualitative detection of the nucleocapsid protein of SARS-CoV-2 present in human nasopharyngeal swab samples. In a prospective clinical studyA , the SARS-CoV-2 Rapid Antigen 2.0 showed a relative sensitivity of 99.00% (95% CI: 94.55 - 99.97%) and a relative specificity of 99.75% (95% CI: 98.62 - 99.99%). In total, 100 PCR-positive and 402 PCR-negative subjects participated in this study. This included 320 asymptomatic subjects, among whom 34 were positive and 286 were negative; and 182 symptomatic individuals, among whom 66 were positive and 116 were negative. This test is intended as an aid in the diagnosis of SARS‑CoV‑2 infection in individuals with or without symptoms consistent with COVID‑19. This product is intended for professional use in laboratory and near‑patient testing environments. This product is not intended for self‑testing.

SARS-CoV-2 Rapid Antigen Test 2.0 Nasal2 (nasal sampling)
The SARS-CoV-2 Rapid Antigen Test 2.0 Nasal is a rapid chromatographic immunoassay for the qualitative detection of the nucleocapsid protein of SARS-CoV-2 present in human nasal swab samples. In prospective clinical studiesA,B, the SARS-CoV-2 Rapid Antigen 2.0 Nasal showed a relative sensitivity of 95.80% (95% CI: 91.09 - 98.44%) and a relative specificity of 100% (95% CI: 99.25 - 100%). In total, 143 PCR-positive and 487 PCR-negative subjects participated in these studies. This included 320 asymptomatic subjects, among whom 34 were positive and 286 were negative; and 310 symptomatic individuals, among whom 109 were positive and 201 were negative. This test is intended as an aid in the diagnosis of SARS‑CoV‑2 infection in individuals with or without symptoms consistent with COVID‑19. This product is intended for professional use in laboratory and near‑patient testing environments. This product is not intended for self‑testing.

SARS-CoV-2 Antigen Self Test Nasal3
The enhanced SARS-CoV-2 Antigen Self Test Nasal is a so-called lateral flow test for the qualitative detection of SARS-CoV-2 nucleocapsid antigen in human nasal samples. This test is used to detect antigens of the SARS-CoV-2 virus in individuals suspected of having COVID-19. It is designed as a self-test for patients. In prospective clinical studiesA, B, the SARS-CoV-2 Antigen Self Test Nasal showed a relative sensitivity of 95.8% (95% CI: 91.09 - 98.44%) and a relative specificity of 100% (95% CI: 99.25 - 100%). In total, 143 PCR-positive and 487 PCR-negative subjects participated in these studies. This included 320 asymptomatic subjects, among whom 34 were positive and 286 were negative; and 310 symptomatic individuals, among whom 109 were positive and 201 were negative. 128 of the subjects were lay-users, sampling and testing themselves or another lay-user, for example their underaged childrenB.

About antigen testing
An antigen test detects proteins which are structural or functional components of a pathogen and are very specific to that pathogen. In this case, the test would provide a qualitative “yes/no” answer on the presence of the antigen in the patient trial and can be offered as a rapid strip test that is performed by healthcare professionals at the point of care or by individuals at home. If the target antigen (in this case the nucleocapsid protein) is present in sufficient concentrations in the sample, it will bind to specific antibodies and generate a visually detectable signal on the test strip, typically with results ready in 15 minutes.2 A rapid antigen test can reliably detect individuals with a high viral load allowing healthcare professionals to quickly identify those patients at the greatest risk of spreading the infection.

In general, antigen tests have a high specificity, though are not as sensitive as molecular tests that amplify the target DNA or RNA sequence in order to generate a (semi-)quantifiable signal to indicate the presence of the pathogen in a sample. Therefore, to make up for the potential decrease in sensitivity of an antigen test, negative results should be analysed together with additional information, such as the individual’s exposure history, clinical symptoms, and additional test results to help guide the diagnosis and subsequent treatment of the patient.

About Roche’s response to the COVID-19 pandemic
As a leading healthcare company, we are doing all we can to support countries in their fight against COVID-19 and minimising its impact. That is why we are working with governments, policy makers, healthcare professionals and others to help contain the COVID-19 pandemic and make sure patients continue to receive the tests, treatment and care they need.

The pandemic has profoundly raised awareness of the role diagnostics play in COVID-19 diagnosis, treatment development and disease management. Roche has developed and launched more than 20 COVID-19 diagnostics solutions, including polymerase chain reaction (PCR) and rapid antigen and antibody tests. Our solutions serve the entire diagnostic continuum, from high-throughput laboratories to point-of-care and home self-testing, and cover all currently known variants. To help meet global demand, we have supplied more than 1.5 billion tests for COVID-19 since March 2020.

Roche continues to evaluate its existing therapeutic portfolio and is researching future options to help benefit patients with COVID-19. Our IL-6 inhibitor Actemra®/RoActemra® (tocilizumab) has been approved for patients hospitalised with severe COVID-19 in more than 30 countries including the European Union and is authorised for emergency use in the United States. The World Health Organization has prequalified Actemra for use in patients with severe COVID-19, facilitating its availability in low- and middle-income countries. In addition, we have been improving access to Actemra by introducing an international differentiated pricing strategy, providing the medicine at cost for use in low- and middle-income countries and non asserting patents in these regions during the pandemic.

We have also been partnering with Regeneron to jointly develop the antibody combination Ronapreve™ (casirivimab and imdevimab, known as REGEN-COV™ in the US). It has been approved in multiple territories including the European Union, Japan, and Switzerland and authorised for emergency or temporary pandemic use in many countries including the US. The antibody combination has been made available to patients in more than 60 countries, across many geographies including low and middle income countries. As the virus continues to evolve, we are constantly monitoring Ronapreve’s activity against emerging variants of concern, and will share results with health authorities as soon as possible.

Our utmost goal remains to be a trusted partner who acts with urgency to save and Strengthen the lives of patients with COVID-19 and to reduce its burden on society. For more information please visit our COVID-19 response page.

About SD Biosensor
SD Biosensor is a global in-vitro diagnostic company focused on the development of immunoassay and molecular diagnostic products at the POC. Founded in 2010, SD Biosensor has continued to research and develop products that can aid in the fast and accurate diagnosis of patients across the testing journey. Through these innovative products, they are striving to become a leading global in vitro diagnostics company.

For more information, please visit http://www.sdbiosensor.com.

About Roche
Founded in1896 in Basel, Switzerland, as one of the first industrial manufacturers of branded medicines, Roche has grown into the world’s largest biotechnology company and the global leader in in-vitro diagnostics. The company pursues scientific excellence to discover and develop medicines and diagnostics for improving and saving the lives of people around the world. We are a pioneer in personalised healthcare and want to further transform how healthcare is delivered to have an even greater impact. To provide the best care for each person we partner with many stakeholders and combine our strengths in Diagnostics and Pharma with data insights from the clinical practice.

In recognizing our endeavor to pursue a long-term perspective in all we do, Roche has been named one of the most sustainable companies in the pharmaceuticals industry by the Dow Jones Sustainability Indices for the thirteenth consecutive year. This distinction also reflects our efforts to Strengthen access to healthcare together with local partners in every country we work.

Genentech, in the United States, is a wholly owned member of the Roche Group. Roche is the majority shareholder in Chugai Pharmaceutical, Japan.

For more information, please visit www.roche.com.

All trademarks used or mentioned in this release are protected by law.

References
[1] SD Biosensor. (2022). SARS-CoV-2 Rapid Antigen Test 2.0 package insert.
[2] SD Biosensor. (2022). SARS-CoV-2 Rapid Antigen Test 2.0 Nasal package insert.
[3] SD Biosensor. (2022). SARS-CoV-2 Antigen Self Test Nasal package insert.

A) A prospective study in South Korea, where each study participant donated three swab samples - one nasal swab and one nasopharyngeal swab for evaluation on the SARS-CoV-2 Rapid Antigen Test 2.0 Nasal and SARS-CoV-2 Rapid Antigen Test 2.0 tests, and another nasopharyngeal swab for evaluation on the RT-PCR comparator method.

B) A prospective, lay-use study in the United States, where study participants collected a nasal swab trial and tested themselves or for another lay-user. Results of the rapid antigen tests were compared to an RT-PCR comparator method performed on a mid-turbinate nasal swab trial collected by a healthcare personnel.

Roche Group Media Relations
Phone: +41 61 688 8888 / e-mail: media.relations@roche.com

Dr. Nicolas Dunant
Phone: +41 61 687 05 17

Sileia Urech
Phone: +41 79 935 81 48

Dr. Barbara von Schnurbein
Phone: +41 61 687 89 67

Karsten Kleine
Phone: +41 61 682 28 31

Nina Mählitz
Phone: +41 79 327 54 74

Nathalie Altermatt
Phone: +41 61 687 43 05

Roche Investor Relations

Investor Relations North America

Attachment

Tue, 11 Oct 2022 22:35:00 -0500 en-US text/html https://finance.yahoo.com/news/roche-introduce-next-generation-portfolio-050300281.html
Killexams : Dia Mirza is epitome of elegance in black satin shirt, brocade trousers as she attends Global Spa Awards 2022

Dia Mirza consistently makes sleek, put-together, and thoughtful fashion choices. The actor wears fashionable sustainable attire created by in-country Indian designers, modelling both sustainability and flair. The recently held GlobalSpa Awards recognised the select few who stand out in the booming global wellness industry due to their distinguished excellence, as evidenced by qualities and services that outperform any competitors. GlobalSpa magazine, the only magazine in the wellness space, organised the event.

Dia Mirza is epitome of elegance in black satin shirt, brocade trousers as she attends Global Spa Awards 2022

Dia Mirza is serving eye-catching look one after another. She can be seen dressed in a Payal Khandwala outfit to highlight the ageless nature of brocades. Speaking of the specifics of her outfit, Dia is seen donning hand-woven antique silver and black engineered silk brocade trousers. The casual black satin silk shirt and the pants make for the epitome of quiet luxury. Her attire is the ideal combination of a modern silhouette and an ancient craft—stylish it's yet relaxed.

Dia completed the outfit with a silver choker and earrings with an antique silver finish. Tons of bronze and copper were used in the actor's makeup to match the zari threads on her brocade pants. The wonderful thing about trousers is that they go with any formal occasion, whether it is a dinner or a social event. Dia's trousers are a perfect example of this. This set is one you should think about if you're looking for attire that will help you maximise your investment.

SUMMARY OF LOOK DETAILS:

ACTRESS: Dia Mirza

OUTFIT: Payal Khandwala

STYLIST: Theia Tekchandaney

MAKE-UP & HAIR:  Shraddha Mishra

Also Read: Ananya Panday aces monochrome dressing in a black jacket and matching trousers at Swarovski event


BOLLYWOOD NEWS - LIVE UPDATES

Catch us for latest Bollywood News, New Bollywood Movies update, Box office collection, New Movies Release , Bollywood News Hindi, Entertainment News, Bollywood Live News Today & upcoming movies 2022 and stay updated with latest hindi movies only on Bollywood Hungama.

Wed, 28 Sep 2022 06:48:00 -0500 en-US text/html https://www.bollywoodhungama.com/news/features/dia-mirza-epitome-elegance-black-satin-shirt-brocade-trousers-attends-global-spa-awards-2022/ Killexams : Roche introduces next-generation portfolio of SARS-CoV-2 rapid antigen tests (2.0) under CE Mark for self-test and professional use

Roche announced the launch of its next-generation portfolio SARS-CoV-2 rapid antigen tests (2.0) for self-testing and professional use in countries accepting the CE Mark. Distribution of the new rapid test portfolio is projected to begin in the coming weeks.

In doing so, Roche builds upon one of the broadest portfolios of Covid-19 rapid testing solutions with three new test configurations that feature enhanced performance through the use of an improved capture antibody and the addition of new digital data sharing capabilities to all tests. Using nasopharyngeal and nasal swab samples, respectively, the tests deliver reliable results in as few as 15 minutes, aiding in the diagnosis of SARS-CoV-2 infection in individuals with or without symptoms consistent with Covid-19.

“The continued evolution of the SARS-CoV-2 virus and Covid-19 pandemic reinforce the need for individuals and healthcare systems to have access to the most reliable rapid testing solutions possible,” said Thomas Schinecker, CEO, Roche Diagnostics. “As a leader in diagnostic innovation, we are proud to be one of the first among our industry to apply insights gained from the past two years toward a next-generation rapid test portfolio. These tests are ready to support global society as we navigate this next phase of the pandemic.”

The three tests set to launch are:

Professional use: -- SARS-CoV-2 Rapid Antigen Test 2.0 (nasopharyngeal sampling); SARS-CoV-2 Rapid Antigen Test 2.0 Nasal (nasal sampling).

Self-Test: -- SARS-CoV-2 Antigen Self Test Nasal (nasal sampling).

Roche maintains the capacity to provide several tens of millions of each of the tests per month, with the option to quickly build up additional capacity if needed, to address sustained high worldwide demand for rapid testing from governments, healthcare systems and individuals. The next-generation test portfolio will be introduced in partnership with SD Biosensor Inc., with whom Roche has a global distribution agreement and previously launched a range of rapid antigen and antibody tests in more than 50 countries worldwide.

The tests join Roche Diagnostics’s broader Covid-19 portfolio, which includes a wide range of molecular, serological and digital solutions that help diagnose and manage Covid-19 during the initial stages of infection, during the recovery phase, and following the resolution of infection.

Lab testing showed that all three tests can qualitatively detect major variants of concern including Delta and Omicron variants. Emerging variants are continuously monitored.

The SARS-CoV-2 Rapid Antigen Test 2.0 is a rapid chromatographic immunoassay for the qualitative detection of the nucleocapsid protein of SARS-CoV-2 present in human nasopharyngeal swab samples. In a prospective clinical studyA , the SARS-CoV-2 Rapid Antigen 2.0 showed a relative sensitivity of 99.00% (95% CI: 94.55 - 99.97%) and a relative specificity of 99.75% (95% CI: 98.62 - 99.99%). In total, 100 PCR-positive and 402 PCR-negative subjects participated in this study. This included 320 asymptomatic subjects, among whom 34 were positive and 286 were negative; and 182 symptomatic individuals, among whom 66 were positive and 116 were negative. This test is intended as an aid in the diagnosis of SARS-CoV-2 infection in individuals with or without symptoms consistent with Covid-19. This product is intended for professional use in laboratory and near-patient testing environments. This product is not intended for self-testing.

The SARS-CoV-2 Rapid Antigen Test 2.0 Nasal is a rapid chromatographic immunoassay for the qualitative detection of the nucleocapsid protein of SARS-CoV-2 present in human nasal swab samples. In prospective clinical studiesA,B, the SARS-CoV-2 Rapid Antigen 2.0 Nasal showed a relative sensitivity of 95.80% (95% CI: 91.09 - 98.44%) and a relative specificity of 100% (95% CI: 99.25 - 100%). In total, 143 PCR-positive and 487 PCR-negative subjects participated in these studies. This included 320 asymptomatic subjects, among whom 34 were positive and 286 were negative; and 310 symptomatic individuals, among whom 109 were positive and 201 were negative. This test is intended as an aid in the diagnosis of SARS-CoV-2 infection in individuals with or without symptoms consistent with Covid-19. This product is intended for professional use in laboratory and near-patient testing environments. This product is not intended for self-testing.

The enhanced SARS-CoV-2 Antigen Self Test Nasal is a so-called lateral flow test for the qualitative detection of SARS-CoV-2 nucleocapsid antigen in human nasal samples. This test is used to detect antigens of the SARS-CoV-2 virus in individuals suspected of having Covid-19. It is designed as a self-test for patients. In prospective clinical studies A, B, the SARS-CoV-2 Antigen Self Test Nasal showed a relative sensitivity of 95.8% (95% CI: 91.09 - 98.44%) and a relative specificity of 100% (95% CI: 99.25 - 100%). In total, 143 PCR-positive and 487 PCR-negative subjects participated in these studies. This included 320 asymptomatic subjects, among whom 34 were positive and 286 were negative; and 310 symptomatic individuals, among whom 109 were positive and 201 were negative. 128 of the subjects were lay-users, sampling and testing themselves or another lay-user, for example their underaged children B.

An antigen test detects proteins which are structural or functional components of a pathogen and are very specific to that pathogen. In this case, the test would provide a qualitative “yes/no” answer on the presence of the antigen in the patient trial and can be offered as a rapid strip test that is performed by healthcare professionals at the point of care or by individuals at home. If the target antigen (in this case the nucleocapsid protein) is present in sufficient concentrations in the sample, it will bind to specific antibodies and generate a visually detectable signal on the test strip, typically with results ready in 15 minutes.2 A rapid antigen test can reliably detect individuals with a high viral load allowing healthcare professionals to quickly identify those patients at the greatest risk of spreading the infection.

In general, antigen tests have a high specificity, though are not as sensitive as molecular tests that amplify the target DNA or RNA sequence in order to generate a (semi-)quantifiable signal to indicate the presence of the pathogen in a sample. Therefore, to make up for the potential decrease in sensitivity of an antigen test, negative results should be analysed together with additional information, such as the individual’s exposure history, clinical symptoms, and additional test results to help guide the diagnosis and subsequent treatment of the patient.

As a leading healthcare company, we are doing all we can to support countries in their fight against Covid-19 and minimising its impact. That is why we are working with governments, policy makers, healthcare professionals and others to help contain the Covid-19 pandemic and make sure patients continue to receive the tests, treatment and care they need.

The pandemic has profoundly raised awareness of the role diagnostics play in Covid-19 diagnosis, treatment development and disease management. Roche has developed and launched more than 20 Covid-19 diagnostics solutions, including polymerase chain reaction (PCR) and rapid antigen and antibody tests. Our solutions serve the entire diagnostic continuum, from high-throughput laboratories to point-of-care and home self-testing, and cover all currently known variants. To help meet global demand, we have supplied more than 1.5 billion tests for Covid-19 since March 2020.

Roche continues to evaluate its existing therapeutic portfolio and is researching future options to help benefit patients with Covid-19. Our IL-6 inhibitor Actemra/RoActemra (tocilizumab) has been approved for patients hospitalised with severe Covid-19 in more than 30 countries including the European Union and is authorised for emergency use in the United States. The World Health Organization has prequalified Actemra for use in patients with severe Covid-19, facilitating its availability in low- and middle-income countries. In addition, we have been improving access to Actemra by introducing an international differentiated pricing strategy, providing the medicine at cost for use in low- and middle-income countries and non asserting patents in these regions during the pandemic.

We have also been partnering with Regeneron to jointly develop the antibody combination Ronapreve (casirivimab and imdevimab, known as REGEN-COV in the US). It has been approved in multiple territories including the European Union, Japan, and Switzerland and authorised for emergency or temporary pandemic use in many countries including the US. The antibody combination has been made available to patients in more than 60 countries, across many geographies including low and middle income countries. As the virus continues to evolve, we are constantly monitoring Ronapreve’s activity against emerging variants of concern, and will share results with health authorities as soon as possible.

Our utmost goal remains to be a trusted partner who acts with urgency to save and Strengthen the lives of patients with Covid-19 and to reduce its burden on society.

SD Biosensor is a global in-vitro diagnostic company focused on the development of immunoassay and molecular diagnostic products at the POC.

Wed, 12 Oct 2022 17:30:00 -0500 text/html http://pharmabiz.com/ArticleDetails.aspx?aid=153811&sid=2
143-085 exam dump and training guide direct download
Training Exams List